Tess Romero

“Ian, Chris, can you maybe talk a little bit about how you are thinking about what you would still like to get out into the public domain about the profile of a ZETU calendar in your Phase III XTOL-II trial and what the specific publication strategy looks like?”

“Hope you are all well, and thanks so much for taking our question. So taking a step back, as you think about ESC here coming up in a few weeks, What do you believe will be better understood by physicians and investors on the other side of the conference?”

“Hope you are all well, and thanks so much for taking our question. So, just to double-click here on some of these earlier comments, what are the specific items procedurally from now to September 30th that still need to be ticked off to allow for an approval?”

“You know, thinking through the outcome of the Phase II Radiant trial, how should we think about scenarios around effect size here, around your primary endpoint of the SAP H&D, and how should we think about the lower bounds of what could still have a path forward into Phase III?”

“So, as a matter of quick housekeeping, can you just remind us what is the right way to think about the LOE for midi-pivot? And then second, to double-click here, what is the right way to think about how cumulative scripts for AugZesmy should evolve from end of 2Q to end of 3Q?”